PT  - JOURNAL ARTICLE
AU  - Pace, Wilson D.
AU  - Brandt, Elias
AU  - Carter, Victoria A.
AU  - Chang, Ku-Lang
AU  - Edwards, Chelsea L.
AU  - Evans, Alexander
AU  - Fox, Chester
AU  - Gaona, Gabriela
AU  - Han, MeiLan K.
AU  - Kaplan, Alan G.
AU  - Kent, Rachel
AU  - Kocks, Janwillem W. H.
AU  - Kruszyk, Maja
AU  - Le Lievre, Chantal E.
AU  - Li Voti, Tessa
AU  - Mahle, Cathy
AU  - Make, Barry
AU  - Ratigan, Amanda R.
AU  - Shaikh, Asif
AU  - Skolnik, Neil
AU  - Stanley, Brooklyn
AU  - Yawn, Barbara P.
AU  - Price, David B.
TI  - COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry
AID  - 10.1370/afm.2829
DP  - 2022 Jul 01
TA  - The Annals of Family Medicine
PG  - 319--327
VI  - 20
IP  - 4
4099  - http://www.annfammed.org/content/20/4/319.short
4100  - http://www.annfammed.org/content/20/4/319.full
SO  - Ann Fam Med2022 Jul 01; 20
AB  - PURPOSE To describe demographic and clinical characteristics of chronic obstructive pulmonary disease patients managed in US primary care.METHODS This was an observational registry study using data from the Chronic Obstructive Pulmonary Disease (COPD) Optimum Patient Care DARTNet Research Database from which the Advancing the Patient Experience COPD registry is derived. Registry patients were aged ≥35 years at diagnosis. Electronic health record data were collected from both registries, supplemented with patient-reported information/outcomes from the Advancing the Patient Experience registry from 5 primary care groups in Texas, Ohio, Colorado, New York, and North Carolina (June 2019 through November 2020).RESULTS Of 17,192 patients included, 1,354 were also in the Advancing the Patient Experience registry. Patients were predominantly female (56%; 9,689/17,192), White (64%; 9,732/15,225), current/ex-smokers (80%; 13,784/17,192), and overweight/obese (69%; 11,628/16,849). The most commonly prescribed maintenance treatments were inhaled corticosteroid with a long-acting β2-agonist (30%) and inhaled corticosteroid with a long-acting muscarinic antagonist (27%). Although 3% (565/17,192) of patitents were untreated, 9% (1,587/17,192) were on short-acting bronchodilator monotherapy, and 4% (756/17,192) were on inhaled corticosteroid monotherapy. Despite treatment, 38% (6,579/17,192) of patients experienced 1 or more exacerbations in the last 12 months. These findings were mirrored in the Advancing Patient Experience registry with many patients reporting high or very high impact of disease on their health (43%; 580/1,322), a breathlessness score 2 or more (45%; 588/1,315), and 1 or more exacerbation in the last 12 months (50%; 646/1,294).CONCLUSIONS Our findings highlight the high exacerbation, symptom, and treatment burdens experienced by COPD patients managed in US primary care, and the need for more real-life effectiveness trials to support decision making at the primary care level.